Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab

February 02, 2024 By The ASCO Post Staff

Saby George, MD, of Roswell Park Comprehensive Cancer Center, discusses pharmacokinetics, efficacy, and safety results from CheckMate 67T, a phase III trial comparing the use of subcutaneous vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who have received prior systemic therapy (Abstract LBA360).

Related Content